Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harte Hanks (HHS) Cash & Equivalents (2016 - 2025)

Harte Hanks (HHS) has disclosed Cash & Equivalents for 16 consecutive years, with $6.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 9.52% to $6.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.5 million, a 9.52% increase, with the full-year FY2024 number at $9.9 million, down 45.91% from a year prior.
  • Cash & Equivalents was $6.5 million for Q3 2025 at Harte Hanks, up from $4.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $26.5 million in Q1 2021 to a low of $4.8 million in Q2 2025.
  • A 5-year average of $11.8 million and a median of $11.0 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 67.31% in 2021, then surged 92.38% in 2023.
  • Harte Hanks' Cash & Equivalents stood at $15.1 million in 2021, then crashed by 31.51% to $10.4 million in 2022, then soared by 77.19% to $18.4 million in 2023, then plummeted by 45.91% to $9.9 million in 2024, then crashed by 34.47% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for HHS's Cash & Equivalents are $6.5 million (Q3 2025), $4.8 million (Q2 2025), and $9.0 million (Q1 2025).